Analyzing the Pharmacodynamic Substances and the Effects of Yiqihuayu Decotion for Acute Ischemic Stroke (PHYSIS)

• Status: Not yet recruiting
• Trial end date: 2023-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The main purposes of this trial are to analyze the pharmacodynamic substances and the effects of Yiqihuayu Decotion for acute ischemic stroke. The trial is a non-randomized, controlled clinical trial.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ying Gao
• Collaborator: Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing

Criteria

Inclusion Criteria:

• Diagnosis of Acute ischemic stroke;

• Symptom onset of 4 to 6 days;

• 40 ≤ age ≤ 80 years;

• Be conscious and able to cooperate with clinical information gatherers;

• Patient or legally authorized representative has signed informed consent.

Exclusion Criteria:

• Suspected secondary stroke caused by tumor, brain trauma, or hematological diseases;

• Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scale score ≥ 2) ;

• Other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis, rheumatoid arthritis);

• Significant renal or hepatic insufficiency (defined as a serum creatinine concentration, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) value that is twice the upper limit of normal);

• Life expectancy of 3 months or less due to other life-threatening illness (e.g.,advanced cancer)

• Other conditions that render outcomes or follow-up unlikely to be assessed;

• Known to be pregnant or breastfeeding;

• Participating in another clinical study.